Key result
Telomere shortening is linked to ASCVD, but modest effect sizes leave causality uncertain.
This review highlights the need to elucidate the mechanistic foundation of telomere shortening in atherosclerotic cardiovascular disease to determine if it is a causal factor or merely a consequence of aging.
Telomeres shorten with age, the major risk factor for atherosclerotic cardiovascular disease (aCVD). The observation of shorter telomeres in aCVD patients thus suggested that critical telomere shortening may contribute to premature biological aging and aCVD. Therefore, telomere length often is suggested as a causal aCVD risk factor, a proposal supported by recent Mendelian randomization studies; however, epidemiological research has shown disappointingly low effect sizes. It therefore remains uncertain whether telomere shortening is a cause of aCVD or merely a consequence. The authors argue that elucidating the mechanistic foundation of these findings is essential for any possible translation of telomere biology to the clinic. Here, they critically evaluate evidence for causality in animal models and human studies, and review popular hypotheses and discuss their clinical implications. The authors identify 4 key questions that any successful mechanistic theory should address, and they discuss how atherosclerosis-associated local telomere attrition may provide the answers.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2018) conducted a review in Atherosclerotic cardiovascular disease (aCVD). Telomere shortening was evaluated. Telomere shortening is associated with atherosclerotic cardiovascular disease, but epidemiological research shows low effect sizes, leaving its causal role uncertain.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: